Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Completed · Phase 3 · Has a placebo group

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).

Key facts

Study ID
NCT02294058
Run by
Celgene
People needed
1346
Starts
2014-12-03
Expected to finish
2016-12-22
Last updated by the study team
2020-11-25

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.